Boehringer Ingelheim

CureVac secured Gates Foundation backing

CureVac to build plant with Gates Foundation money

By Gareth Macdonald

CureVac will build a manufacturing facility for mRNA vaccines after a $52m (€46m)  Gates Foundation investment that also brings an IPO one step closer according to majority shareholder Dietmar Hopp.

Boehringer Ingelheim licenses CureVac mRNA vaccine for up to $600m

Boehringer Ingelheim licenses CureVac mRNA vaccine for up to $600m

By Zachary Brennan

Boehringer Ingelheim will pay mRNA drug developer CureVac up to €465m ($600m) for an exclusive global license and development collaboration on CureVac’s potential mRNA vaccine in early clinical development for the treatment of lung cancer. 

Best biopharma bosses

Best biopharma bosses

By Anna Lewcock

There have been a few changes in the top ten employers according to
leading journal Science's annual survey of the best
companies to work for in the biotech, biopharma, pharmaceutical and
related industries.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers